MedPath

Questionnaire on the clinical praxis of percutaneous endoscopic gastrostomy insertion in patients with autosomal recessive polycystic kidney disease (ARPKD)

Conditions
Q61.1
Polycystic kidney, autosomal recessive
Registration Number
DRKS00011012
Lead Sponsor
niversitätsklinikum Köln
Brief Summary

Extract from published paper: 196 participants from 39 countries shared their opinion. 45% of participants support gastrostomy insertion in all ARPKD patients, but portal hypertension is considered to be a contraindication by a subgroup of participants. Patient-specific data was provided for 38 patients indicating complications of gastrostomy that were in principal comparable to non-ARPKD patients. Bleeding episodes were reported in 3/38 patients (7.9%). Two patients developed additional severe complications. Gastrostomy was retrospectively considered as the right decision for the patient in 35/38 (92.1%) of the cases.

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete
Sex
All
Target Recruitment
196
Inclusion Criteria

The interviewed colleagues work at centers for pediatric nephrolgy or pediatric hepatology in Europe and diagnosed ARPKD due to clinical criteria in the patients. The data of ARPKD patients are questioned in an anonymous and retrospective manner.

Exclusion Criteria

not willing to participate

Study & Design

Study Type
observational
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
It is the aim of the questionnaire to collect data regarding the current practice of PEG (percutaneous endoscopic gastrostomy) implantations in ARPKD (autosomal recessive polycystic kidney disease) patients in European pediatric centers and the experiences obtained. Benefit and risks of the intervention are evaluated in a retrospective manner in order to create first evidence regarding this important therapy in patients suffering from this serious disease of early childhood.
Secondary Outcome Measures
NameTimeMethod
© Copyright 2025. All Rights Reserved by MedPath